Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Fate Therapeutics Inc.FATE · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $318.9M[1]
Standard universeinsiderevenue above $1M and assets above $10M[1-2]
Warningsshort runway, thin data · fortress balance sheetnot computable: distress
Inputs computable5 of 14
Graded fromfilings received through Feb 26, 2026225 days before the rescan; every figure keyed to the SEC receipt date
Last close$2.132026-10-08; market equity $255.2M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$1$2$3NovDecJanFebMarAprMayJunJulAugSepOct$2.13
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2014nonen/aQ2
Mar 21, 2019nonen/aQ3
Mar 21, 2021nonen/aQ4
Mar 21, 2024nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Feb 26, 2026; the document on sec.gov.

We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients. We have pioneered a therapeutic approach that we generally refer to as cellular programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, we generate a clonal master iPSC line for use as a renewable source of starting material for the manufacture of cell therapies; through the manufacturing process, we direct the fate of the clonal master iPSC line to produce our cell th...

Warnings [top]

Short runway. cash runway is 3.8 months[3]
Thin data. 5 of 14 grade factors are computable; minimum is 7
Fortress balance sheet. cash minus debt is 172,034,000 USD; Altman Z is not used[4-5]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 49.0
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(8.0%)[1,6-8](6.6%)49.08112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 31.5
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-primenot computable(0.31)
one or more required annual facts are missing
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio5.79x[9-10]2.96x31.58392025-12-31
Growth and financing, sleeve percentile 70.9
Revenue growth, three-year compound(59.0%)[2,11-13]10.0%96.64152025-12-31
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(23.3%)[1,8,14-15]2.1%87.37042025-12-31
Net share issuance, one year1.5%[16-17]2.5%28.86342026-02-19

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month89.7%8.0%86hotter than 86 of 100 peers
Distance from 52-week high(31.5%)(31.4%)49closer to its high than 49 of 100 peers
EBIT to enterprise value(61.2%)(1.5%)11pricier than 89 of 100 peers
Free cash flow yield(43.9%)(1.0%)13pricier than 87 of 100 peers
Book value to price0.600.2875pricier than 25 of 100 peers
Sales to price0.030.3110pricier than 90 of 100 peers
Composite equity issuance, five years24.5%20.3%53more equity-funded than 53 of 100 peers
Relative strength against the sector, log excess return0.43(0.14)86ahead of 86 of 100 peers

Inputs: market equity $255.2M; EBIT -$147.7M; free cash flow -$112.0M; book equity $153.4M; sales $6.6M; debt $18.5M; cash $32.4M[18].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(30.9%)✗ fail[6,8]
Operating cash flow above zero-$106.1M✗ fail[7]
Return on assets improved5.9 pts✓ pass[6,8,14,19]
Operating cash flow exceeds net income$30.2M✓ pass[6-7]
Long-term leverage felln/a[1,8,14]
Current ratio improved(179.2 pts)✗ fail[9-10,20-21]
No new shares issued1.5%✗ fail[16-17]
Gross margin improvedn/a
Asset turnover improved(1.2 pts)✗ fail[2,8,11,14]
Cash, filings, liquidity
Cash and equivalents$32.4M[3]
Operating cash flow, four quarters-$101.9M[3,7,22-25]
Months of runway3.8
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing57
10-Q received Aug 13, 2026
Median daily dollar volume$3.3M
63 sessions
Days since newest grade input225

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$318.9M2025-12-312026-02-2610-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$6.6M2025-12-312026-02-2610-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$32.4M2026-06-302026-08-1310-Qfiling · viewer · series
4cashus-gaap:CashAndCashEquivalentsAtCarryingValue$190.5M2018-12-312021-02-2410-Kfiling · viewer · series
5total debtus-gaap:LongTermDebt$18.5M2018-12-312019-03-0510-Kfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$136.3M2025-12-312026-02-2610-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$106.1M2025-12-312026-02-2610-Kfiling · viewer · series
8assetsus-gaap:Assets$440.7M2024-12-312026-02-2610-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$208.7M2025-12-312026-02-2610-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$36.1M2025-12-312026-02-2610-Kfiling · viewer · series
11revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$13.6M2024-12-312026-02-2610-Kfiling · viewer · series
12revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$63.5M2023-12-312025-03-0510-Kfiling · viewer · series
13revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$96.3M2022-12-312024-02-2610-Kfiling · viewer · series
14assetsus-gaap:Assets$506.2M2023-12-312025-03-0510-Kfiling · viewer · series
15assetsus-gaap:Assets$705.6M2022-12-312024-02-2610-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding116,263,4592026-02-192026-02-2610-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding114,597,4252025-02-252025-03-0510-Kfiling · viewer · series
18shares outstandingdei:EntityCommonStockSharesOutstanding119,820,5142026-08-062026-08-1310-Qfiling · viewer · series
19net incomeus-gaap:NetIncomeLoss-$186.3M2024-12-312026-02-2610-Kfiling · viewer · series
20current assetsus-gaap:AssetsCurrent$291.9M2024-12-312026-02-2610-Kfiling · viewer · series
21current liabilitiesus-gaap:LiabilitiesCurrent$38.5M2024-12-312026-02-2610-Kfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$23.4M2026-06-302026-08-1310-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$30.8M2026-03-312026-05-1310-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$82.8M2025-09-302025-11-1310-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$58.4M2025-06-302026-08-1310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.